Therapy News and Research

RSS

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014

CT angiography provides accurate assessment of arterial plaque in diabetic patients

Imaging of the coronary arteries with computed tomography (CT) angiography provides an accurate assessment of arterial plaque and could have a dramatic impact on the management of diabetic patients who face a high risk of heart attacks and other cardiovascular events, according to a new multicenter study published online in the journal Radiology.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Small gene embedded in large gene contributes to development of acute myeloid leukemia

A small gene that is embedded in a larger, well-known gene is the true leukemia-promoting force usually attributed to the larger gene, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

22 Apr 2014

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.

21 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Scientists lay groundwork for understanding immune responses in Lyme disease patients

A team of scientists led by Johns Hopkins and Stanford University researchers has laid the groundwork for understanding how variations in immune responses to Lyme disease can contribute to the many different outcomes of this bacterial infection seen in individual patients. A report on the work appears online April 16 in PLOS One.

21 Apr 2014

Wolters Kluwer Health launches dental drug interactions screening tool with Medication Safety Check feature

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has launched an enhanced dental drug interactions screening tool with a new Medication Safety Check feature, allowing professionals to screen for drug-drug, drug-allergy, and duplicate therapy interactions and review safe medication options.

21 Apr 2014

BRI scientists receive grant to study new approach to blocking metastatic breast cancer

Benaroya Research Institute at Virginia Mason recently received a grant to research how blocking a particular molecule in metastatic breast cancer reduces both the growth of primary tumors and the number of lung metastases.

21 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Rural residents who commonly seek treatment for advanced stages of colorectal cancer have been thought to lack access to cancer screening and adjuvant therapy. ... Several theories have been postulated to explain these findings, some of which include low socioeconomic status, lower educational attainment, lack of insurance coverage, underinsurance, and travel distance to health care facilities.

21 Apr 2014

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

21 Apr 2014

Researchers receive $3.7M NIH grant to develop anti-smoking program for HIV-infected smoker

Montefiore Medical Center researchers have received a $3.7 million grant from the National Institute on Drug Abuse at the National Institutes of Health (NIH) to develop an anti-smoking program for HIV-infected smokers.

21 Apr 2014

Northwestern Medicine study provides new insights on tissue scarring in scleroderma

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

21 Apr 2014

Dopamine replacement therapy linked with decline in depressed Parkinson patients' cognitive function

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's disease (PD).

19 Apr 2014

LSTM researchers to conduct extensive research on HIV and schistosomiasis coinfection in African children

Researchers from LSTM have called for more research to be carried out into HIV and schistosomiasis coinfection in children in sub-Saharan Africa.

18 Apr 2014

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.

18 Apr 2014

XBiotech announces results from Phase I/II oncology study

XBiotech is announcing that results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston, TX were published today in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix™, XBiotech's novel, non-cytotoxic, anti-tumor therapy.

18 Apr 2014

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Kessler Foundation has been named awardee of a three-year grant for $1.8 million from the Department of Defense Spinal Cord Injury Research Program. Gail Forrest, PT, PhD, is principal investigator for the randomized, double-blinded, controlled, multi-site clinical trial, which will test strategies to improve bone and muscle strength after spinal cord injury. Dr. Forrest is assistant director of Human Performance & Engineering Research at Kessler Foundation.

18 Apr 2014

Agios begins AG-348 Phase 1 study to treat PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers.

18 Apr 2014

Therapy News and Research

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

CT angiography provides accurate assessment of arterial plaque in diabetic patients

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Small gene embedded in large gene contributes to development of acute myeloid leukemia

Synageva announces publication of LAL Deficiency review in Atherosclerosis

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Scientists lay groundwork for understanding immune responses in Lyme disease patients

Wolters Kluwer Health launches dental drug interactions screening tool with Medication Safety Check feature

BRI scientists receive grant to study new approach to blocking metastatic breast cancer

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

Researchers receive $3.7M NIH grant to develop anti-smoking program for HIV-infected smoker

Northwestern Medicine study provides new insights on tissue scarring in scleroderma

Dopamine replacement therapy linked with decline in depressed Parkinson patients' cognitive function

LSTM researchers to conduct extensive research on HIV and schistosomiasis coinfection in African children

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

XBiotech announces results from Phase I/II oncology study

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Agios begins AG-348 Phase 1 study to treat PK deficiency

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News